
AstraZeneca head of R&D exits role
pharmafile | June 12, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Briggs Morrison
Briggs Morrison who joined AstraZeneca in 2012 and played an instrumental part in defending its takeover by Pfizer, is abruptly leaving the UK firm.
According to AstraZeneca Morrison will shortly be the chief executive of a ‘small, privately-held pharmaceutical company’ instead.
Morrison was said to have applied a more aggressive approach to R&D and led several high-profile oncology projects – as well as bringing in new pipeline deals.
His departure is a surprise, as he joined AstraZeneca relatively recently and had become an integral part of chief executive Pascal Soriot’s plans to bolster its pipeline of new drugs.
Soriot will take on Morrison’s responsibilities for global development at the company until a successor is named.
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






